PMID- 37971045 OWN - NLM STAT- MEDLINE DCOM- 20240125 LR - 20240125 IS - 1678-4170 (Electronic) IS - 0066-782X (Print) IS - 0066-782X (Linking) VI - 120 IP - 8 DP - 2023 TI - Effect on the Quality of Life of Patients with Heart Failure and Reduced/Preserved Ejection Fraction Using Sacubitril/Valsartan. PG - e20220611 LID - S0066-782X2023000800309 [pii] LID - 10.36660/abc.20220611 [doi] LID - e20220611 AB - BACKGROUND: Heart failure (HF) management has markedly improved, but a clinically meaningful improvement in functional capacity and quality of life is perhaps more important for patients than living longer. OBJECTIVE: This study aimed to review the improvement in quality of life with sacubitril/valsartan in patients with HF and reduced/preserved ejection fraction (EF) from prospective clinical trials. METHODS: PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) and prospective cohort studies published from inception to July 2021. A total of 6 clinical trials and 16854 patients with HF were included. The primary outcome was the change from baseline in KCCQ clinical summary score. The secondary outcomes were scores in other domains of KCCQ, the occurrence of serious adverse events (AEs), and overall mortality. P-values <0.05 were considered statistically significant. RESULTS: Treatment of sacubitril/valsartan showed significantly higher KCCQ-CSS compared to the control (WMD=0.975, 95% CI: 0.885, 1.064, p<0.001; I2=94.8%, pheterogeneity<0.001). A significant decrease in the mortality rate was observed in the sacubitril/valsartan group compared to the control group (RR=0.895, 95%CI:0.831, 0.965, p=0.004; I2=43.6%, pheterogeneity=0.150). Nevertheless, no significant reduction in the occurrence of serious AEs was found among HF patients treated with sacubitril/valsartan compared to the control group (RR=0.950, 95%CI: 0.879, 1.027, p<0.001; I2=68.1%, pheterogeneity=0.024). CONCLUSIONS: Our study demonstrated that sacubitril/valsartan might significantly improve the HRQL compared to other treatments according to the results in KCCQ-CSS and some subdomains in the KCCQ index during the follow-up in patients with HF. FAU - Huang, Yuanrui AU - Huang Y AD - Department of Pharmacy, Banan Hospital of Traditional Chinese Medicine, Chongqing - China. FAU - Wu, Xu AU - Wu X AD - Department of Geriatrics, Banan Hospital of Traditional Chinese Medicine, Chongqing - China. FAU - Li, Xingyu AU - Li X AD - Department of Cardiology, Chongqing Hospital of Traditional Chinese Medicine, Chongqing - China. FAU - Liu, Zhengzhong AU - Liu Z AD - Department of Cardiology, Banan Hospital of Traditional Chinese Medicine, Chongqing - China. FAU - Li, Yunyi AU - Li Y AUID- ORCID: 0000-0003-2422-0107 AD - Department of Pharmacy, Chongqing Hospital of Traditional Chinese Medicine, Chongqing - China. LA - eng LA - por PT - Journal Article TT - Efeito na Qualidade de Vida de Pacientes com Insuficiencia Cardiaca e Fracao de Ejecao Reduzida/Preservada em Uso de Sacubitril/Valsartan. DEP - 20231110 PL - Brazil TA - Arq Bras Cardiol JT - Arquivos brasileiros de cardiologia JID - 0421031 RN - 0 (Aminobutyrates) RN - 0 (Angiotensin Receptor Antagonists) RN - 0 (Drug Combinations) RN - 17ERJ0MKGI (sacubitril) RN - 0 (Tetrazoles) RN - 80M03YXJ7I (Valsartan) SB - IM MH - Humans MH - Aminobutyrates/therapeutic use MH - Angiotensin Receptor Antagonists/therapeutic use MH - Drug Combinations MH - *Heart Failure/drug therapy MH - Quality of Life MH - Stroke Volume MH - *Tetrazoles/therapeutic use MH - Valsartan/adverse effects MH - Clinical Trials as Topic PMC - PMC10519244 OAB - BACKGROUND: Heart failure (HF) management has markedly improved, but a clinically meaningful improvement in functional capacity and quality of life is perhaps more important for patients than living longer. OBJECTIVE: This study aimed to review the improvement in quality of life with sacubitril/valsartan in patients with HF and reduced/preserved ejection fraction (EF) from prospective clinical trials. METHODS: PubMed, Embase, and the Cochrane Library were searched for randomized controlled trials (RCTs) and prospective cohort studies published from inception to July 2021. A total of 6 clinical trials and 16854 patients with HF were included. The primary outcome was the change from baseline in KCCQ clinical summary score. The secondary outcomes were scores in other domains of KCCQ, the occurrence of serious adverse events (AEs), and overall mortality. P-values <0.05 were considered statistically significant. RESULTS: Treatment of sacubitril/valsartan showed significantly higher KCCQ-CSS compared to the control (WMD=0.975, 95% CI: 0.885, 1.064, p<0.001; I(2)=94.8%, p(heterogeneity)<0.001). A significant decrease in the mortality rate was observed in the sacubitril/valsartan group compared to the control group (RR=0.895, 95%CI:0.831, 0.965, p=0.004; I(2)=43.6%, p(heterogeneity)=0.150). Nevertheless, no significant reduction in the occurrence of serious AEs was found among HF patients treated with sacubitril/valsartan compared to the control group (RR=0.950, 95%CI: 0.879, 1.027, p<0.001; I(2)=68.1%, p(heterogeneity)=0.024). CONCLUSIONS: Our study demonstrated that sacubitril/valsartan might significantly improve the HRQL compared to other treatments according to the results in KCCQ-CSS and some subdomains in the KCCQ index during the follow-up in patients with HF. OABL- eng COIS- Potencial conflito de interesse Nao ha conflito com o presente artigo EDAT- 2023/11/17 15:31 MHDA- 2023/11/20 06:54 PMCR- 2023/08/28 CRDT- 2023/11/16 08:36 PHST- 2022/08/31 00:00 [received] PHST- 2023/06/14 00:00 [accepted] PHST- 2023/11/20 06:54 [medline] PHST- 2023/11/17 15:31 [pubmed] PHST- 2023/11/16 08:36 [entrez] PHST- 2023/08/28 00:00 [pmc-release] AID - S0066-782X2023000800309 [pii] AID - 10.36660/abc.20220611 [doi] PST - epublish SO - Arq Bras Cardiol. 2023 Nov 10;120(8):e20220611. doi: 10.36660/abc.20220611. eCollection 2023.